Harvard Bioscience Inc (NASDAQ: HBIO) open the trading on Wednesday, with a bit cautious approach as it glided -23.84% to $0.28, before settling in for the price of $0.37 at the close. Taking a more long-term approach, HBIO posted a 52-week range of $0.29-$3.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -3.49%. Meanwhile, its Annual Earning per share during the time was -18.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.67%. This publicly-traded company’s shares outstanding now amounts to $44.21 million, simultaneously with a float of $37.41 million. The organization now has a market capitalization sitting at $12.57 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4242, while the 200-day Moving Average is $1.7048.
Harvard Bioscience Inc (HBIO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Instruments & Supplies industry. Harvard Bioscience Inc’s current insider ownership accounts for 15.39%, in contrast to 60.20% institutional ownership. According to the most recent insider trade that took place on Jun 13 ’24, this organization’s Chief Executive Officer bought 10,000 shares at the rate of 2.91, making the entire transaction reach 29,100 in total value, affecting insider ownership by 3,111,091. Preceding that transaction, on Jun 06 ’24, Company’s Chief Executive Officer bought 20,000 for 3.07, making the whole transaction’s value amount to 61,400. This particular insider is now the holder of 3,101,091 in total.
Harvard Bioscience Inc (HBIO) Earnings and Revenue Records
Harvard Bioscience Inc’s EPS increase for this current 12-month fiscal period is 16.67% and is forecasted to reach 0.06 in the upcoming year.
Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators
Let’s observe the current performance indicators for Harvard Bioscience Inc (HBIO). It’s Quick Ratio in the last reported quarter now stands at 0.40. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.14. Similarly, its price to free cash flow for trailing twelve months is now 33.07.
In the same vein, HBIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.32, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be 0.06 at the market close of one year from today.
Technical Analysis of Harvard Bioscience Inc (HBIO)
[Harvard Bioscience Inc, HBIO] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 37.07% While, its Average True Range was 0.0509.
Raw Stochastic average of Harvard Bioscience Inc (HBIO) in the period of the previous 100 days is set at 0.15%, which indicates a major fall in contrast to 0.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 140.76% that was higher than 101.03% volatility it exhibited in the past 100-days period.
